This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LA JOLLA, Calif.,
Nov. 7, 2012 /PRNewswire/ --
Regulus Therapeutics Inc. (
NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of
Douglas E. Williams, Ph.D. to its Board of Directors. Concurrently,
Stanley T. Crooke, M.D., Ph.D., Chairman of the Board and CEO of Isis Pharmaceuticals, Inc., and
Barry E. Greene, President and Chief Operating Officer of Alnylam Pharmaceuticals, Inc., have each stepped down from the Board of Directors and their respective Board committees.
"I want to thank Stan and Barry for their leadership and for their many contributions during the past formative years of the company. During their service on the Board, Regulus has transitioned from an up-start to an emerging publicly traded biopharmaceutical company," said
John Maraganore, Ph.D., Chairman of Regulus' Board of Directors. "I would also like to welcome Doug to the Board and look forward to his contributions as we continue to build a great company."
"I also want to thank Stan and Barry for their wonderful service and many contributions to the Board," said
Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. "I'd also like to welcome Doug to the Board. He is a recognized biotech leader with a proven track record of more than twenty years in drug development, research and operations. Given our recently completed public offering and focus on clinical development, Doug's addition to our Board comes at the right time as we advance multiple microRNA programs toward the clinic."
"This is an exciting time to join the outstanding team at Regulus," said Dr. Williams. "Regulus is in a strong position to capture the transformative potential of microRNA therapeutics and create powerful, first-in-class medicines."